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Abstract
Functional severity in ankylosing spondylitis (AS) patients is variable and difficult to predict early. The aim of our study was
to assess whether a combination of baseline clinical factors and genetic markers may predict the development of severe
functional status in AS. We performed a cross-sectional association study on AS patients included in the Spanish National
Registry of Spondyloarthropathies—REGISPONSER. Bath Ankylosing Spondylitis Functional Index (BASFI) was standardized
by adjusting for disease duration since the first symptoms (BASFI/t). We considered as severe functional status the values of
BASFI/t in the top of the 60th (p60), 65th (p65), 70th (p70), and 75th (p75) percentile. We selected 384 single nucleotide
polymorphisms (SNPs) distributed in 190 genes to be analyzed. The study cohort included 456 patients with mean age
50.8(610.5) years and with mean disease duration since first symptoms 24.7 (610.1) years. Older age at disease onset and
neck pain at baseline showed statistical significant association with severe BASFI/t. Polymorphisms associated in the allele
frequencies test with severe BASFI/t in all classifications were: rs2542151 (p60 [P= .04], p65 [P= .04], p70 [P= .001] and p75
[P= .001]) and rs2254441 (p60 [P= .004], p65 [P= .02], p70 [P= .01] and p75 [P,.001]).. Genotype association, after
adjustment for covariates, found an association in three of the four patients’ classifications for rs2542151 and in two of the
classifications for rs2254441.Forward logistic regression did not identify any model with a good predictive power for severe
functional development. In our study we identified clinical factors and 24 polymorphisms associated with development of
severe functional status in AS patients. Validation of these results in other cohorts is required.
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Introduction
Ankylosing spondylitis (AS) is a chronic progressive inflamma-
tory disease affecting the spine and peripheral joints. It is largely
confirmed that susceptibility to AS is genetically determined with
HLA-B27 as a major genetic contributor to the disease [1–3] and
that environmental factors also play a role in susceptibility to the
disease. In the last few years, several other genes have been
reported to be involved in AS susceptibility [4–9].
Although the assessment of physical function is only one of
several aspects of assessing disease severity, it is one of the most
important measures of structural damage outcome in AS, as it
directly influences the quality of life of patients and the economic
costs of the disease [10–11]. Impairment of physical function can
be subdivided into a reversible and an irreversible component. In
this concept the reversible component is due to disease activity
(signs and symptoms of the disease) and the irreversible component
is due to structural damage that has occurred as a consequence of
the disease, such as syndesmophytes and vertebral bridging.
Functional severity was found to be independently determined by
both the reversible factors such as disease activity and the
irreversible factors such as structural damage [12] but the loss of
functional capacity in each patient was not predictable from early
disease stages [13].
There is evidence that several clinical parameters such as hip
involvement, disease duration, erythrocyte sedimentation rate
(ESR), C-reactive protein (CRP) levels, smoking, and lower
socioeconomic status are associated with worse function [13–14].
Nevertheless, much of the variability in disease functional severity
in AS remains unexplained, suggesting that genetic factors could
have a greater influence than environmental factors on AS
progression [13].
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A genetic component has been demonstrated for AS functional
severity [15]. However, very little is known about the specific genes
or genetic markers inside and outside the major histocompatibility
gene complex (MHC) involved in the functional component of the
disease [16–20].
Understanding the genetic basis of functional severity in AS
would be of major value to differentiate at early stages patients at
high risk of severe functional impairment and patients with a lower
risk. Thus, clinicians could better select and optimize the
preventive and therapeutic approach for each patient as of the
time of diagnosis of the disease by objectively distributing high cost
treatments.
Taking into consideration the fact that impairment of physical
function may be partially controlled by the appropriate treatment,
the aim of our study was to identify the baseline clinical and
genetic factors that determine individual development of func-
tional severity in AS.
Materials and Methods
Patients with AS
We performed a cross-sectional association study on Spanish AS
patients which were recruited from 25 hospitals which participated
in the Spanish National Spondyloarthropathies Registry (REGIS-
PONSER) [21]. Patients fulfilled the modified New York Criteria
for AS [22] and had at least 10 years of follow-up from the first
symptoms of the disease. Baseline characteristics of the patients at
the beginning of the disease were recorded as potential prognostic
predictors. Specifically, clinical and demographic data, sex, age at
disease onset, family history of spondyloarthropathies (SpA), initial
symptoms of SpA (inflammatory low back pain, neck pain,
enthesitis, dactylitis, tarsitis, sacroiliac syndrome, coxitis, lower
limb arthritis, and upper limb arthritis), and the number of initial
SpA symptoms.
Demographic and clinical characteristics of the AS
population
The studied cohort included 456 AS patients (348 males and
108 females) with a mean age of 50.8610.5 years, 26.169.1 years
at disease onset and 34.6611.4 years at diagnosis. The average
time of evolution, from disease onset, was 24.7610.1 years. HLA-
B27 was positive in 84.9% of the patients and 19.3% had a family
history of spondyloarthropathies (SpA). Patients had mean BASFI
at baseline 4.062.8, with mean BASFI/t (years) of 0.1760.13.
Functional phenotype
To measure functional impairment we used the BASFI score,
standardized by adjusting for disease duration since first symp-
toms, denominated here BASFI/t. BASFI is a validated index that
focuses on 10 questions pertaining to function, measured on a
visual analog scale (VAS). The mean of the 10 questions generates
the score, with 10 denoting worst possible functional status [23].
There are no validated threshold values for classifying AS
patients into mild or severe categories according to their BASFI
score standardized by disease duration (BASFI/t). Therefore, to
define functional severity we performed four association analyses
using the x2-test with different criteria. Based on the opinion of the
clinicians who participated in this study, who estimated that
approximately 25% to 40% of AS patients had severe functional
damage, we defined as severe functional status the values of
BASFI/t in the top 60th (p60), 65th (p65), 70th (p70) or 75th (p75)
percentiles. The cut-off values for BASFI/t severe phenotype for
each percentile were: 0.19 for p60, 0.21 for p65, 0.22 for p70, and
0.25 for p75 respectively.
HLA-B27 typing and SNP genotyping
Genomic DNA was isolated from saliva samples using the
OrageneTM DNA Self-Collection kit (DNA Genotek Inc., Ottawa,
Canada), according to the manufacturer’s extraction protocol. All
samples were tested for the presence of the HLA-B27 allele by
conventional PCR using the primers reported by Olerup et al [24].
A region of 236 bp on exon 8 from the p53 gene was used as an
internal control for the performance of the PCR [25].
After an extensive bibliographic search we selected 384 SNPs
distributed in 190 genes to be analyzed in this study. We selected
all the SNPs previously reported in Caucasians as associated with
AS or with other SpA (psoriatic arthritis, juvenile idiopathic
arthritis, reactive arthritis, undifferentiated arthritis, and inflam-
matory bowel disease–associated spondyloarthropathy). Besides
those SNPs, we included some SNPs in genes described in the
literature as associated to other autoimmune diseases and to bone-
related disorders, since we considered them as potential candidates
to be implicated in AS severity. Finally, we included tag SNPs in
genes from the metabolic pathways of the two most important
genes considered to be involved in AS: ERAP1 and IL-23R.The
tag SNPs were selected from the HapMap CEU panel (the minor
allele frequency at each locus was required to be .0.05 in
Caucasian population, with an r2-value of ,0.8 between adjacent
markers).SNP genotyping was performed using the Illumina
Golden gate genotyping platform (Illumina, Inc., San Diego,
CA, USA) [26].
Statistical analysis
Statistical analysis was performed with SPSS v 15.0 (SPSS,
Chicago, IL, USA) and SVS v 7.3.1 (Golden Helix Inc., Bozeman,
Montana, USA) softwares.
All quantitative data are presented as mean and standard
deviation (6 SD) and all qualitative data as absolute frequencies
and percentages. To assess the association between clinical
variables and BASFI/t severe phenotype an unvaried analysis
was performed using the chi-square (x2) test for categorical
variables and the unpaired t test for continuous variables.
A test for deviation from Hardy-Weinberg equilibrium (HWE)
was performed for each SNP. Pruning of the initial genotype
dataset with default parameters (exclusion of SNPs with poor
genotype cloud clustering, of SNPs with call-rate ,85%, of SNPs
with severe deviation from HWE (P,.0001) and of samples with
call rate ,85%) led to 456 samples and 344 SNPs [27–30].
Association test between allele and genotype frequencies and
BASFI/t severe phenotype was performed by the chi-square (x2)
test. P-values were calculated using a single-value permutation test
(1000 permutations). The minor allele frequency at all loci was
above 10%…Logistic regression analysis was used to discard
weather the baseline clinical factors associated with severe function
could be confounding for the association between BASFI/t severe
phenotype and the SNPs genotypes. P values of ,.05 were
considered statistically significant and p values of (.05$p,.1)
borderline.
Clinical factors and SNPs were then studied by means of
multivariate logistic regression. Individual P values of the SNPs
and of the clinical variables were ranked and only those most
significantly associated with the severe functional phenotype were
included in the multivariate analysis as potential predictors (P,.1
in the allele frequencies association test).. The multivariate analysis
was performed for all four defined classifications of functional
severity (p60, p65, p70, and p75). BASFI/t was considered as
dependent variable and baseline clinical variables and SNPs were
included as predictors. The predictive discrimination of the models
was tested both by Hosmer-Lemeshow statistic and the receiver
R.Schiotis et al. Severe Functional Status in AS
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operating characteristic curve (ROC) with 95% confidence
interval (CI). An area under the ROC curve (AUC) above 0.75
was considered as an indicator of a good predictive precision of the
model.
Ethical approval
This study was approved by the Ethics Committee of ‘‘Reina
Sofia’’ University Hospital, Co´rdoba and ‘‘Puerta de Hierro
Majadahonda’’ University Hospital, Madrid, Spain. Each patient
signed an informed consent form upon inclusion in REGISPON-
SER-AS, in accordance with the fundamental principles set out in
the Declaration of Human Rights in Helsinki.
Results
Baseline clinical variables and SNPs associated with
functional severity in AS patients
Of the baseline clinical variables analyzed, the association with
BASFI/t severe phenotype for neck pain and older age at disease
onset was found to be statistically significant. A slight association
was also found for low back pain (p60) and HLA-B27 (p65 and
p70) (Table 1).
In the allele frequencies test, from the SNPs analyzed, we
identified 24 polymorphisms associated with functional severe
phenotype in at least one of the patient classifications. Two SNPs
showed consistent association with BASFI/t and were significantly
associated in all four patient classifications: rs2542151 in the
protein tyrosine phosphatase non-receptor type 2 (PTPN2) gene
[p60 (P= .046), p65 (P= .006), p70 (P= .002) and p75 (P= .001)]
and rs2254441 in the proline-serine-threonine phosphatase-
interacting protein 1 (PSTPIP1) gene [p60 (P= .036), p65
(P= .017), p70 (P= .010) and p75 (P= .001)]. Five SNPs
(rs10065172. rs2268624, rs4986790, rs4986791, rs3736228) were
associated with BASFI/t in three of the four patient classifications
and eight polymorphisms (rs6887695, rs17481856, rs2280153,
rs1217414, rs4958847, rs2227982, rs17551710, rs1248634) in two
classifications. The other nine polymorphisms (rs6822844,
rs11959820, rs3117222, rs660895, rs1061622 rs13151961,
rs27044, rs6254, rs743572) were found significantly associated
with BASFI/t for only one of the patient classifications (Table 2).
As we found that age at disease onset and neck pain at onset
were the clinical factors associated with BASFI/t severe pheno-
type, they were entered in the logistic regression modeling as
covariates. The results of the genotype frequencies test showed
that the SNP rs2542151 in the PTPN2 gene was significantly
associated to BASFI/t in three of the four patients’ classifications
after adjustment for age at disease onset and neck pain (Table 2).
There were other four SNPs with significant or borderline
genotype associations in two of the patients’ classifications after
adjustment for age at disease onset and neck pain, rs2254441 in
the PSTPIP1 gene, rs2268624 in the TGFB3 gene, and rs4986790
and rs4986791 in the TLR4 gene. The rest of SNPs were not
associated to BASFI/t in the genotype test after correction for age
at disease onset and neck pain at onset.
For further investigate the association between clinical-genetic
variables and functional severe phenotype in AS, we performed a
multivariate analysis using BASFI/t (severe/mild) as dependent
variable and as covariates the clinical and genetic variables most
significantly associated with BASFI/t ((p,0,1 in the allele
frequencies association test). We did not find any model with a
good predictive accuracy for BASFI/t for any of the patient
classifications, p60, p65, p70, and p75 as none of the ROC curves
of the predictive models attained an area under the curve (AUC)
above 0.75.
Discussion
This is a pioneering study performed on daily clinical patients
which sought the clinical and genetic factors of influence in the
development of functional severity in AS. Maintaining a good
functional status is the main aim of pharmacologic treatment in
current clinical practice. Reliable markers that could be applied
early in the disease course to identify patients with potential severe
functional outcome would be of major value for clinicians to
consequently select the most suitable treatment strategy. The
results of our study found that older age and neck pain at disease
onset and several new SNPs, particularly rs2542151 (PTPN2) and
rs2254441 (PSTPIP1), are predictors of severe functional impair-
ment in AS. However, the combination of the genetic and clinical
factors identified in our study was not sufficient to develop a
predictive model with a good accuracy for AS functional outcome;
therefore, additional predictors are required.
We found neck pain and older age at disease onset as the main
clinical variables associated with severe AS functional status. Neck
pain at onset, which in AS may arise from either mechanical or
inflammatory lesions, presented a consistent association in all four
patient classifications studied [p75 (P= .040), p70 (P= .002), p65
(P= .004), p60 (P= .011)]. To the best of our knowledge, this is the
first study which has found neck pain as a predictor for AS
functionality. There is conflicting evidence about the role of age at
disease onset as a predictor of disease severity, with some studies
finding an association and others failing to support this [31–35].
Patients included in our study were young adults at disease onset,
with mean age of 26.169.1 years. Interestingly, we found a
statistically significant association between older age at disease
onset and BASFI/t severe phenotype (p75, p70, p65, p60;
P,.001). This result is in accordance with a recent study which
found that the likelihood of developing more severe radiographic
damage was greater among patients with an older age at disease
onset [36]. The authors suggested that this association could result
if patients with an older age at disease onset are asymptomatic
early in their illness or if they have occasional or milder symptoms,
which might cause them to underestimate the duration of their
disease. Supporting previous studies [36–38], we found that HLA-
B27 was poorly associated with functional severity; thus, we only
identified statistically significant association in two of the
percentiles studied [p65 (P= .050), p70 (P= .049)]. Surprisingly,
we did not find coxitis at baseline to be associated with
development of severe physical function as found in several
Table 1. Baseline clinical variables associated with functional
severity in AS patients.
p value
Clinical
Variable BASFI/t p75 BASFI/t p70 BASFI/t p65 BASFI/t p60
Age at
disease onset
,.001 ,.001 ,.001 ,.001
Neck pain .040 .002 .004 .011
Low back
pain
NS NS NS .030
HLA-B27 NS .050 .049 NS
NS- no statistically significant.
doi:10.1371/journal.pone.0043428.t001
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previous studies that sought clinical predictors of functional
disability in AS [39–41].
Recent genome-wide association studies have provided valuable
evidence supporting the involvement of genetic factors in the
pathogenesis and prognosis of autoimmune diseases. The two
major SNPs found in this study to be associated with development
of severe physical function are located in the autoinflammatory
genes PTPN2 and PSTPIP1. Our study found a consistent
association between AS functional severity and the C allele of
the SNP rs2542151 in the PTPN2 gene. PTPN2 is a remarkable
gene, since it appears to influence most cells involved in the
development of the immune system [42]. PTPN2 encodes the T
cell protein tyrosine phosphatase TCPTP, a key negative regulator
of inflammatory responses. Abnormalities in tyrosine phosphory-
lation have been found to be involved in the pathogenesis of
numerous human diseases, such as developmental defects,
neoplastic disorders, immunodeficiency, and autoimmunity [43].
The C allele of the SNP rs2542151 at PTPN2 gene, which we
found to influence AS functional severity, was previously found to
be associated with other autoimmune diseases, such as Crohn’s
disease, type 1 diabetes, and rheumatoid arthritis [44–45]. The
fact that the SNP rs2542151 in PTPN2 is associated with different
aspects of autoimmune diseases suggests that these diseases,
including AS, could share common pathogenic mechanisms.
Another consistent association between poor physical function
of AS patients and SNPs was found for the A allele of the
polymorphism rs2254441 in the PSTPIP1 gene. PSTPIP1 is a
cytoskeleton-associated adaptor protein that regulates innate and
adaptive immune responses. Although this pathway has been
traditionally related to diseases associated with pyoderma gang-
raenosum, such as aseptic abscesses syndrome and chronic
inflammatory bowel disease (IBD) [46], the SNP rs2254441 has
been recently reported as associated with psoriatic juvenile
idiopathic arthritis, a disease included in the spondyloarthropa-
thies group together with AS and IBD [47].
In addition to SNPs in PTPN2 and PSTPIP1 genes, a milder
association with BASFI/t severe phenotype was observed for SNPs
in the immunity-related GTPase family M protein (IRGM),
transforming growth factor beta 3 (TGFB3), Toll-like receptor 4
(TLR4), and LDL receptor related protein 5 (LRP5) genes. IRGM
is a human immunity-related GTPase which confers autophagic
defense against intracellular pathogens such as Mycobacterium
tuberculosis (BCG) and Salmonella typhimurium. This gene’s polymor-
phism rs10065172, which we found associated with AS functional
Table 2. SNPs associated with functional severity in AS patients.
Allele frequencies test, p value1
SNP Name Gene Symbol Risk Allele BASFI/t p75 BASFI/t p70 BASFI/t p65 BASFI/t p60
rs2542151 PTPN2 C 0.001* 0.002* 0.006* 0.046#
rs2254441 PSTPIP1 A 0.001* 0.010{ 0.017# 0.036#
rs2268624 TGFB3 G 0.002* 0.017* 0,032# NS
rs4986790 TLR4 G 0.008{ 0.009{ 0.037# NS
rs4986791 TLR4 A 0.011* 0.006* 0.031# NS
rs10065172 IRGM G NS 0,014# 0,012# 0.006*
rs3736228 LRP5 A 0.049# 0,051# 0,056# NS
rs6887695 IL12B C NS 0.038# 0.037# NS
rs17481856 ERAP1 G NS 0.035# NS 0.038#
rs2280153 WISP3 G NS NS 0.032# 0.014*
rs1217414 PTPN22 G NS 0.049# NS 0.034{
rs4958847 IRGM G NS NS 0.042# 0.027#
rs2227982 PDCD1 A NS 0.019{ 0,044# NS
rs17551710 COL6A1 A 0.043# NS NS 0.048#
rs1248634 DLG5 A NS 0.047# 0.043# NS
rs6822844 IL21 A NS NS NS 0.031#
rs11959820 PPARBC1B C NS NS NS 0.017*
rs3117222 LOC646702 G NS NS NS 0.018*
rs660895 HLA-DRB1 G NS NS 0.044{ NS
rs1061622 TNFRSF1B A NS NS NS 0.050#
rs13151961 KIAA1109 G NS NS NS 0.042#
rs27044 ERAP1 C NS NS NS 0.020*
rs6254 PTH A 0,025# NS NS NS
rs743572 CYP17A1 A 0.032# NS NS NS
1- The p-values shown correspond to the allele frequencies test corrected by a single-value permutation test.
The symbols represent the results of the genotype frequencies association test before and after a logistic regression analysis using the age at disease onset and neck
pain as covariates:
*Significant genotype association (p,0.05) after logistic regression analysis with adjustment for age at disease onset and neck pain;
{Borderline genotype association (0.05$p,0.1) after logistic regression analysis with adjustment for age at disease onset and neck pain;
#Significant genotype association (p,0.05) was lost after logistic regression analysis with adjustment for age at disease onset and neck pain.
doi:10.1371/journal.pone.0043428.t002
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severity, has been associated with increased tuberculosis risk in
some populations [42] and is a well-established risk factor for IBD
[43].
In addition to SNPs in PTPN2 and PSTPIP1 genes, a milder
association with BASFI/t severe phenotype was seen for SNPs in
the transforming growth factor beta 3 (TGFB3) and Toll-like
receptor 4 (TLR4) genes. Regarding TGFß3, high serum levels of
this protein have been linked to osteoporosis risk [48] and
polymorphisms in TGFß have been found to be associated with
ossification of the posterior longitudinal ligament of the spine
(OPLL) in the Japanese population [49]. To the best of our
knowledge this is the first report which linked risk from allele G of
rs2268624 in TGFß3 with development of functional severity in
AS.
The association of the SNPs rs4986790 and rs4986791 in the
TLR4 gene could represent the involvement of the innate immune
system in the progression of AS. Dysregulation of Toll-like
receptor (TLR)-related pathways, specifically upregulation of
TLR4 and TLR5, has been reported in AS [50].
Of particular interest was to find an association between severe
functional impairment and rs3736228 in LRP5 gene, since a
recently published study in the Chinese population has found
several other SNPs in LRP5 to be associated with AS susceptibility
[47]. The SNP rs3736228 was also identified to be associated with
gender dependent bone mass formation and may be implicated in
the adaptation of bone to mechanical load in humans [48]. As far
as we are concerned, this is the first report in which a link between
polymorphisms involved in bone formation and AS functional
severity is identified.
The strength of this study lies in the large number of clinically
well characterized AS patients. However, our study has some
limitations. First, we performed a cross-sectional study in which we
did not analyze the treatment administered to patients as a
possible factor that influences physical outcome, since we did not
have reliable data about which patients were on a specific therapy
prior to their inclusion in the study. The lack of information about
the treatment could have introduced some bias. Secondly, in spite
of the clinical and genetic factors found to influence AS functional
prognosis, we could not achieve a good predictive model for
development of severe functional status by combining these
factors. Thus, further research in this area in other cohorts or in
prospective studies is needed to confirm which of these genetic
markers in combination with clinical factors could identify an
accurate predictive model for AS functional severity.
In conclusion, our results confirm that severe functional status in
AS is associated with both clinical and genetic factors. We found
that older age and neck pain at disease onset, lymphoid tyrosine
phosphatase (PTPN2)-rs2542151, proline-serine-threonine phos-
phatase interacting protein1 (PSTPIP1)-rs2254441 polymorphisms,
are potential predictors of the development of severe functional
status in AS patients. Validation of these results in other cohorts is
required.
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